Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium Chemical Formula: Structural Characteristics, Pharmaceutical Applications, And Formulation Optimization

NOV 17, 202662 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose sodium, a cross-linked polymer derivative of carboxymethylcellulose sodium, represents a critical pharmaceutical excipient widely employed in oral solid dosage forms. Its chemical structure, characterized by internal cross-linking of carboxymethyl groups, imparts unique disintegration and dissolution-enhancing properties that are essential for optimizing drug bioavailability. Understanding the molecular composition, structural modifications, and functional mechanisms of croscarmellose sodium is fundamental for advanced pharmaceutical formulation development and quality control in drug delivery systems.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Composition And Structural Characteristics Of Croscarmellose Sodium

Croscarmellose sodium is fundamentally a cross-linked polymer of carboxymethylcellulose sodium, wherein the cellulose backbone undergoes chemical modification through carboxymethylation followed by controlled cross-linking 378. The base structure originates from cellulose, a linear polysaccharide composed of β(1→4)-linked D-glucose units. During synthesis, hydroxyl groups on the anhydroglucose units are partially substituted with carboxymethyl groups (-CH₂-COONa), introducing anionic character and water solubility to the polymer chain 2.

The defining structural feature distinguishing croscarmellose sodium from its non-cross-linked precursor is the introduction of covalent bridges between polymer chains. This cross-linking process typically employs bifunctional reagents such as propylene glycol or epichlorohydrin under controlled pH conditions (pH 1.0–3.0) 2. The cross-linking density—defined as the number of cross-link points per polymer chain—critically determines the swelling capacity, mechanical strength, and disintegration kinetics of the final material. Patent literature indicates that optimal cross-linking is achieved when the reaction is conducted in aqueous or aqueous-alcoholic media, with subsequent purification steps to remove unreacted cross-linking agents and soluble oligomers 2.

The chemical formula of croscarmellose sodium cannot be represented by a single molecular formula due to its polymeric and cross-linked nature. Instead, it is characterized by:

  • Repeating unit structure: Modified anhydroglucose units with variable degrees of carboxymethyl substitution (typically 0.6–0.95 carboxymethyl groups per glucose unit).
  • Cross-linking bridges: Covalent linkages (e.g., ether or ester bonds) connecting polymer chains at intervals determined by the cross-linking agent and reaction conditions.
  • Sodium counterions: Associated with carboxylate groups (-COO⁻Na⁺), providing ionic character and pH-dependent swelling behavior.

Analytical techniques such as Fourier-transform infrared spectroscopy (FTIR), nuclear magnetic resonance (NMR), and X-ray diffraction (XRD) are employed to characterize the degree of substitution, cross-linking density, and crystallinity of croscarmellose sodium batches. Compliance with pharmacopeial standards (e.g., Chinese Pharmacopoeia 2010 edition, USP, EP) requires strict control of these structural parameters to ensure batch-to-batch consistency and functional performance 2.

Synthesis Routes And Process Optimization For Croscarmellose Sodium

The preparation of croscarmellose sodium involves a multi-step synthetic pathway that integrates carboxymethylation, cross-linking, and purification stages. A representative synthesis protocol, as disclosed in patent literature, comprises the following key steps 2:

Step 1: Carboxymethylation Of Cellulose

Native cellulose is treated with sodium hydroxide (NaOH) to generate alkali cellulose, which subsequently reacts with monochloroacetic acid (ClCH₂COOH) or its sodium salt. This etherification reaction introduces carboxymethyl groups onto the cellulose backbone. Critical process parameters include:

  • Alkali concentration: Typically 20–40% NaOH (w/w) to ensure complete swelling and accessibility of hydroxyl groups.
  • Molar ratio: Monochloroacetic acid to anhydroglucose unit ratio of 1.5:1 to 3:1, controlling the degree of substitution.
  • Reaction temperature: 50–70°C for 2–4 hours to achieve optimal substitution without polymer degradation.

Step 2: Cross-Linking Reaction

The carboxymethylcellulose sodium intermediate is dispersed in a solvent (water or aqueous ethanol), and the pH is adjusted to 1.0–3.0 using hydrochloric acid or citric acid 2. A cross-linking agent, such as propylene glycol, is then added. The acidic pH protonates carboxylate groups, reducing electrostatic repulsion and facilitating inter-chain proximity for cross-linking. Key parameters include:

  • Cross-linking agent concentration: 0.5–5% (w/w) relative to polymer mass, with higher concentrations yielding denser networks.
  • Reaction time: 1–3 hours at 60–80°C, monitored by viscosity and swelling index measurements.
  • pH control: Maintaining pH 1.0–3.0 is critical; deviations can lead to incomplete cross-linking or polymer hydrolysis.

Step 3: Neutralization, Washing, And Drying

Post-reaction, the mixture is neutralized to pH 6.5–7.5 using sodium hydroxide or sodium carbonate, precipitating the cross-linked polymer. The product is washed extensively with water or aqueous ethanol to remove residual cross-linking agents, salts, and soluble oligomers 2. Final drying is conducted at 60–80°C under vacuum or in a fluidized bed dryer to achieve moisture content below 10% (w/w), ensuring stability and flowability.

Quality Control And Analytical Characterization

The synthesized croscarmellose sodium must meet stringent pharmacopeial specifications, including:

  • Degree of substitution (DS): Typically 0.6–0.95, determined by titration or NMR.
  • Swelling capacity: Measured as volume increase in water (typically 400–800% of original volume), indicative of cross-linking density.
  • Particle size distribution: D50 values of 30–100 μm for optimal tablet disintegration.
  • Residual cross-linking agent: Below 10 ppm (e.g., propylene glycol) to comply with safety standards.
  • Microbial limits: Total aerobic count <1000 CFU/g, absence of pathogens (E. coli, Salmonella).

Patent CN104447314A emphasizes that products prepared via this optimized route exhibit disintegration performance equivalent to imported reference standards (e.g., Ac-Di-Sol®), validating the method's industrial applicability 2.

Functional Mechanisms: Disintegration And Dissolution Enhancement In Pharmaceutical Formulations

Croscarmellose sodium functions primarily as a superdisintegrant in oral solid dosage forms, facilitating rapid tablet or capsule breakdown upon contact with aqueous media 134568. Its mechanism of action is multifaceted, involving physical swelling, wicking, and deformation recovery:

Swelling-Driven Disintegration

Upon exposure to water or gastrointestinal fluids, croscarmellose sodium rapidly absorbs liquid (up to 4–8 times its weight), causing volumetric expansion 8. The cross-linked network prevents complete dissolution, instead generating internal hydrostatic pressure that disrupts the tablet matrix. This swelling is pH-dependent: at gastric pH (1–3), carboxylate groups are partially protonated, reducing electrostatic repulsion and limiting swelling; at intestinal pH (6–7), full ionization maximizes swelling and disintegration force 37.

Wicking And Capillary Action

The fibrous, porous structure of croscarmellose sodium particles creates capillary channels that draw aqueous media into the tablet core via capillary action. This wicking effect accelerates liquid penetration, particularly in hydrophobic formulations, enhancing the dissolution rate of poorly water-soluble drugs 8.

Deformation Recovery

During tablet compression, croscarmellose sodium particles undergo elastic deformation. Upon hydration, these particles recover their original shape, exerting mechanical stress on the tablet matrix and promoting fragmentation 37.

Quantitative Performance Data

Patent and formulation studies provide quantitative benchmarks for croscarmellose sodium efficacy:

  • Disintegration time: Tablets containing 6–14% (w/w) croscarmellose sodium typically disintegrate within 30–120 seconds in USP Apparatus 1 (basket method) at 37°C 8.
  • Dissolution enhancement: For entacapone formulations, increasing croscarmellose sodium from 5% to 12% (w/w) improved 30-minute dissolution from 65% to >90% 8.
  • Optimal concentration range: 5–10% (w/w) for most immediate-release tablets; 10–14% (w/w) for formulations with hydrophobic APIs or high drug loads 1568.

Comparative Advantage Over Alternative Disintegrants

Croscarmellose sodium demonstrates superior performance compared to other disintegrants such as sodium starch glycolate or non-cross-linked carboxymethylcellulose sodium. Its cross-linked structure provides:

  • Higher swelling capacity without gel formation, preventing viscosity-related dissolution retardation 37.
  • pH-independent disintegration across physiological pH ranges (1–7.5), ensuring consistent performance in fed and fasted states 8.
  • Compatibility with direct compression, requiring no pre-treatment or granulation in many formulations 1456.

Formulation Design Principles: Integrating Croscarmellose Sodium Into Oral Solid Dosage Forms

The incorporation of croscarmellose sodium into pharmaceutical formulations requires careful consideration of drug properties, excipient interactions, and manufacturing processes. Patent literature provides detailed case studies illustrating best practices 1456.

Case Study 1: CETP Inhibitor Formulation (Hydrophobic API)

A composition comprising S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate (a hydrophobic, water-unstable CETP inhibitor) and croscarmellose sodium was developed to address stability and bioavailability challenges 1456. Key formulation strategies included:

  • Hygroscopic polymer matrix: Croscarmellose sodium (5–7% w/w) was combined with hydroxypropyl methylcellulose (HPMC), microcrystalline cellulose (MCC), and micronized crospovidone to create a chemically protective, physically stable matrix 156.
  • Granulation process: Wet granulation using HPMC solution (0.5% w/w in water or 10–30% ethanol/70–90% water) ensured uniform API distribution and enhanced tablet hardness 456.
  • Intragranular vs. extragranular addition: Croscarmellose sodium was added both intragranularly (during granulation) and extragranularly (during final blending) to optimize disintegration kinetics; a 50:50 split yielded optimal performance 16.
  • Quantitative composition: API 48–55% w/w, croscarmellose sodium 5–7% w/w, HPMC 10–15% w/w, MCC 20–25% w/w, crospovidone micronized 3–5% w/w, colloidal silicon dioxide 0.5–1% w/w, sodium stearylfumarate 0.5–1% w/w 156.

This formulation achieved >85% dissolution within 30 minutes and maintained chemical stability (>95% API assay) for 24 months at 25°C/60% RH 156.

Case Study 2: 2,2-Dichloro-12-(4-Chlorophenyl)-Dodecanoic Acid Stabilization

A pharmaceutical composition comprising 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid (or its sodium salt) and croscarmellose sodium was developed to enhance chemical stability 37. The formulation leveraged croscarmellose sodium's dual role as disintegrant and stabilizing agent:

  • Stabilization mechanism: Croscarmellose sodium's hygroscopic nature maintained a low-moisture microenvironment around the acid-labile API, reducing hydrolytic degradation 37.
  • Optimal ratio: API to croscarmellose sodium ratio of 2:1 to 1:15 (w/w) provided both stability and disintegration performance 37.
  • Excipient compatibility: Lactose, microcrystalline cellulose, and hydroxypropylcellulose were used as additional excipients; no incompatibilities were observed in accelerated stability studies (40°C/75% RH, 6 months) 37.

Case Study 3: Entacapone And Nitecapone Formulations

An oral compacted composition comprising entacapone or nitecapone and croscarmellose sodium (10–14% w/w) was developed to maximize dissolution rate 8. Key findings included:

  • Concentration-dependent dissolution: Increasing croscarmellose sodium from 6% to 12% (w/w) improved 30-minute dissolution from 70% to >90% for entacapone tablets 8.
  • Superiority over alternatives: Croscarmellose sodium outperformed sodium starch glycolate and low-substituted hydroxypropyl cellulose in head-to-head dissolution studies 8.
  • Manufacturing robustness: Direct compression and wet granulation methods both yielded acceptable tablets, with wet granulation providing superior content uniformity for low-dose formulations 8.

General Formulation Guidelines

Based on patent and literature data, the following guidelines are recommended for incorporating croscarmellose sodium into immediate-release tablets:

  1. Concentration: 5–10% (w/w) for standard formulations; 10–14% (w/w) for poorly soluble or high-dose APIs 1568.
  2. Addition method: Split addition (50% intragranular, 50% extragranular) optimizes disintegration without compromising tablet hardness 16.
  3. Particle size: D50 of 30–100 μm ensures uniform distribution and consistent disintegration 2.
  4. Compression force: Maintain below 15 kN to preserve croscarmellose sodium's elastic recovery capacity 8.
  5. Moisture control: Final tablet moisture content should be 2–5% (w/w) to prevent premature swelling during storage 156.

Applications Of Croscarmellose Sodium Across Therapeutic Categories

Croscarmellose sodium's versatility as a pharmaceutical excipient extends across diverse therapeutic areas, with documented applications in cardiovascular, metabolic, neurological, and anti-infective drug formulations.

Cardiovascular And Metabolic Disorders

Croscarmellose sodium is extensively used in formulations targeting dyslipidemia and atherosclerosis. The CETP inhibitor formulations described in patents WO2012059447A1, EP2635273A1, and AU2011322651B2 exemplify its application in managing cardiovascular risk 1456. These formulations address the challenge of delivering hydrophobic, chemically unstable APIs by embedding them in a hygroscopic polymer matrix that simultaneously protects against degradation and enhances dissolution. Clinical implications include improved bioavailability (area under the curve increased by 30–50% compared to non-optimized formulations) and reduced inter-subject variability 156.

For researchers developing next-generation lipid-modifying agents, the following considerations are critical:

  • API lipophilicity: Log P >4 typically requires croscarmellose sodium concentrations ≥8% (w/w) to achieve therapeutic dissolution rates 156.
  • Dose proportionality: High-dose formulations (>200 mg API per tablet) benefit from increased croscarmellose sodium (10–12% w/w) to maintain disintegration kinetics despite higher tablet mass 16.
  • Food effect mitigation: Croscarmellose sodium's pH-independent swelling reduces food-related bioavailability variability, a key advantage for drugs requiring consistent exposure 8.

Neurological Disorders: Parkinson's Disease

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
F. HOFFMANN-LA ROCHE AGOral solid dosage forms for hydrophobic and water-unstable cardiovascular drugs requiring enhanced bioavailability and chemical protection in immediate-release tablet formulations.CETP Inhibitor Tablet FormulationCroscarmellose sodium (5-7% w/w) combined with hygroscopic polymers provides rapid disintegration within 30-120 seconds and achieves >85% dissolution within 30 minutes while maintaining chemical stability (>95% API assay) for 24 months at 25°C/60% RH.
LUZHOU NORTH CHEMICAL INDUSTRY CO. LTD.Pharmaceutical excipient manufacturing for use as superdisintegrant in immediate-release tablets requiring rapid disintegration and dissolution enhancement across diverse therapeutic categories.Croscarmellose Sodium (Pharmaceutical Excipient)Cross-linked carboxymethylcellulose sodium prepared via propylene glycol cross-linking at pH 1.0-3.0 exhibits swelling capacity of 400-800% and meets Chinese Pharmacopoeia 2010 standards with disintegration performance equivalent to imported reference standards.
KOWA COMPANY LTDOral solid dosage forms containing acid-labile active pharmaceutical ingredients requiring dual functionality of chemical stabilization and rapid disintegration in immediate-release formulations.2,2-Dichloro-12-(4-chlorophenyl)-dodecanoic Acid Stabilized FormulationCroscarmellose sodium at API to excipient ratio of 2:1 to 1:15 (w/w) functions as both disintegrant and stabilizing agent, maintaining low-moisture microenvironment to reduce hydrolytic degradation while ensuring rapid tablet disintegration.
ORION CORPORATIONParkinson's disease treatment formulations requiring maximum dissolution rate enhancement for catechol derivative drugs in immediate-release oral compacted compositions with robust manufacturing performance.Entacapone/Nitecapone Tablet FormulationCroscarmellose sodium at 10-14% w/w concentration increases dissolution rate from 70% to >90% at 30 minutes for entacapone tablets, demonstrating superior performance compared to sodium starch glycolate and low-substituted hydroxypropyl cellulose.
Reference
  • A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium
    PatentActiveIL225780A0
    View detail
  • Sodium croscarmellose and preparation method thereof
    PatentInactiveCN104262649A
    View detail
  • Pharmaceutical composition comprising 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid
    PatentInactiveNZ534471A
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png